TrialPloS one2013

Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.

Freddie M Kibengo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.